HC Wainwright Predicts Daré Bioscience FY2029 Earnings
Equities researchers at HC Wainwright issued their FY2029 earnings estimates for shares of Daré Bioscience in a research note ...
HC Wainwright Has Negative Outlook for Genelux Q1 Earnings
Research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Genelux in a report released on Monday, March 31st ...
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.
Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings)
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.72, a high estimate of $202.00, and a low estimate of $75.00. This current ...
Fintel on MSN23h
HC Wainwright & Co. Initiates Coverage of Kairos Pharma (KAPA) with Buy Recommendation
Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...
Arcutis strategic valued enhanced by patent win, says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao views the agreement of joint stipulation between Arcutis Biotherapeutics (ARQT) and Padagis to the ongoing ...
Zura Bio price target lowered to $3 from $5 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Zura Bio (ZURA) to $3 from $5 and keeps a Buy rating on the shares ...